NCT05289167 - Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions

Graft-versus-host Disease

Interventions

DRUG

Cyclophosphamide

50 mg/kg IV over 1 hour on Day +3 and +4

DRUG

Abatacept

"Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28"

DRUG

Bortezomib

1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.

Trial Locations (1)

10016

Northwell Health, New Hyde Park